Developer docs
API playgroundTry for free, no card

Search company profiles

Mediwhale

Full company profile

uuid0000val

Namestring
Mediwhale
Legal namestring
Mediwhale Inc.
Websiteurl
mediwhale.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Mediwhale is a Seoul-based medical AI company founded in October 2016 that develops deep learning software for analyzing retinal fundus photographs to predict cardiovascular and metabolic disease risk. The company's core product, Dr. Noon CVD, is the world's first regulatory-approved AI medical device for cardiovascular disease risk prediction using retinal imaging, demonstrating predictive accuracy comparable to cardiac CT scans without radiation exposure. The technology is built on proprietary deep learning models trained on over 2.1 million clinical data points across diverse populations and imaging devices, validated through 50+ peer-reviewed publications. The product portfolio includes Dr. Noon CVD (cardiovascular risk prediction), Dr. Noon Fundus (automated detection of glaucoma, cataracts, and retinal diseases), and pipeline product Dr. Noon CKD (chronic kidney disease prediction under regulatory review).

The company operates a B2B healthcare software business model, selling AI diagnostic examinations to hospitals, clinics, and health screening centers on a per-test basis (50,000-100,000 KRW per examination in Korea as a non-reimbursable test) supplemented by software licensing through distribution partnerships. Primary go-to-market is direct enterprise sales to major hospitals (Yonsei Severance, Naeun Hospital, Catholic University St. Vincent Hospital) complemented by channel partnerships with Dong-A ST for Korean clinic distribution and Topcon Korea Medical for bundled fundus camera solutions. The platform is commercially deployed across 111-170+ medical institutions in 8+ regulatory regions (Korea, EU CE MDR, UK MHRA, Australia TGA, Singapore HSA, Malaysia, Indonesia, India), with active expansion into Europe (Italy, Poland, Germany, Netherlands, France), Middle East (Dubai via GluCare.Health), Southeast Asia, and the US via FDA De Novo pursuit. The company has raised approximately 51.2 billion KRW (~$38M USD) across multiple funding rounds from 2020 to 2026 and is preparing for a KOSDAQ listing under the technology special track.

Short descriptiontext

Mediwhale is a Seoul-based medical AI company that develops deep learning software for retinal image analysis to predict cardiovascular and metabolic disease risk, serving hospitals and clinics across 8+ regulatory regions with its flagship Dr. Noon CVD product.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
retinal AI diagnostics, cardiovascular risk prediction, medical imaging software, AI medical devices, disease prevention AI
Industry4 codes
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAD
Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHDAAAEAH
Medical Imaging AI
NAICS code2 codes
  • Software Publishers5132
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical AI Diagnostics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1AI Diagnostic Software (Per Test/Examination)
TypeSubscription Recurring
Description

Mediwhale generates revenue through the sale of its Dr. Noon AI diagnostic examinations to healthcare institutions. Hospitals and clinics pay for the AI analysis service when conducting retinal scans on patients. In Korea, Dr. Noon CVD is available as a non-reimbursable diagnostic test at 50,000-100,000 KRW per examination. The company is pursuing insurance coverage through the Health Insurance Review and Assessment Service evaluation.

mediwhale.com
2Software Licensing and Distribution
TypeLicensing Royalties
Description

Revenue generated through distribution partnerships where partners like Dong-A ST and Topcon distribute Dr. Noon solutions to hospitals and clinics across Korea. Partners handle sales and distribution while Mediwhale provides the software.

mediwhale.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Others
Pricing details1 tier
1Dr. Noon CVD examination per session
ModelUnit PricingBilling cadencePay-as-you-go
Notes

50,000-100,000 KRW per examination in Korea as non-reimbursable diagnostic. Price covers retinal photography plus AI analysis for cardiovascular risk assessment.

mediwhale.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1Dr. Noon CVD
Description

Retina-based AI risk prediction solution that assesses future cardiovascular disease risk using retinal imaging, with accuracy comparable to cardiac CT scans.

mediwhale.com
+2 more records
Core offering1 text field

Mediwhale develops and sells AI-powered medical device software that analyzes retinal fundus photographs to predict cardiovascular disease risk and detect eye diseases. Its flagship Dr. Noon platform uses deep learning trained on over 2.1 million clinical data points to deliver non-invasive, radiation-free risk assessments with accuracy comparable to cardiac CT scans.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Cardiovascular risk prediction accuracy comparable to cardiac CT (coronary artery calcium scoring)
+3 more records
Product overview1 text field

Mediwhale offers a unified platform of retinal AI diagnostic solutions for preventive healthcare. The core product Dr. Noon CVD predicts cardiovascular disease risk through retinal imaging analysis with accuracy comparable to cardiac CT scans. Companion product Dr. Noon Fundus provides automatic detection of eye diseases (glaucoma, cataracts, retinal diseases). Pipeline product Dr. Noon CKD extends the platform to chronic kidney disease prediction. Reti-CVD was the original product name for the cardiovascular risk assessment AI that evolved into Dr. Noon CVD. All products leverage deep learning models trained on over 2.1 million clinical data points across diverse populations and imaging devices.

Product and service4 records
1Dr. Noon CVD
CategoryCardiovascular AI Diagnostics
Description

Retina-based AI software as a medical device that assesses future cardiovascular disease risk by analyzing retinal photographs, with predictive accuracy comparable to cardiac CT scans. Used by hospitals, clinics, and health screening centers for non-invasive, radiation-free CVD risk assessment.

2Dr. Noon Fundus
CategoryOphthalmic AI Diagnostics
Description

Retina-based AI solution that automatically detects three types of eye diseases—glaucoma, cataracts, and retinal diseases—from a single retinal photograph. Designed for use by ophthalmology clinics and primary care providers.

3Dr. Noon CKD
CategoryRenal AI Diagnostics
Description

Retinal AI solution for chronic kidney disease prediction, designated as an innovative medical device in Korea. Currently under regulatory review with MFDS for approval.

4Dr. Noon (Europe)
CategoryIntegrated Retinal AI Platform
Description

Unified retinal AI solution combining eye disease diagnosis and cardiovascular risk prediction, CE MDR certified for commercialization in EU member states.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Dong-A ST
Strategic tierStrategic PartnerTypeChannel Partner/ Reseller/ Distributor
Description

Strategic partnership for distribution of Mediwhale's AI retinal diagnostics across Korea. Following the partnership, adoption across internal medicine clinics increased rapidly with over 40,000 total examinations conducted.

mediwhale.com
Strategic tierDistribution PartnerTypeChannel Partner/ Reseller/ Distributor
Description

Supply partnership with Topcon Korea Medical (subsidiary of Revenio Group) for Dr. Noon CVD bundled with Topcon fundus cameras (TRC-NW400) to hospitals and clinics.

Strategic tierRegional PartnerTypeChannel Partner/ Reseller/ Distributor
Description

Dubai-based diabetes clinic partnership for Dr. Noon CVD supply and UAE market expansion. Includes collaboration on UAE market entry and Dr. Noon CKD efficacy research.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Eyenuk develops FDA-cleared AI for retinal image analysis (EyeArt for diabetic retinopathy). Directly comparable retinal AI SaMD vendor with similar regulatory milestones, hospital and clinic deployment model, and clinical screening value proposition.

TypeBroad incumbent
Description

Vuno is a Korean medical AI company (KOSDAQ-listed) developing deep-learning solutions across multiple imaging and clinical data modalities. Peer in terms of geographic/regulatory context (Korea), target customer (hospitals), and SaMD commercialization model.

TypeBroad incumbent
Description

HeartFlow provides non-invasive coronary CT-derived fractional flow reserve (FFR-CT) for cardiovascular disease diagnosis. Comparable as an established cardiac diagnostics SaMD company targeting similar specialist and primary care prescribers, though HeartFlow's modality (CT) differs from Mediwhale's retinal imaging.

TypeDirect peer
Description

AEYE Health develops AI-based retinal screening for systemic and ocular disease detection, including cardiovascular risk assessment from fundus images. Directly comparable to Mediwhale in technology modality (retinal imaging + deep learning), customer base (primary care and endocrinology), and SaMD regulatory pathway.

TypeBroad incumbent
Description

Cleerly applies AI to coronary CT angiography for cardiovascular disease risk assessment. Comparable as an AI-CVD-diagnostics competitor positioning non-invasive imaging as a CT alternative—same end-point (CVD risk prediction) via a different imaging modality, addressing the same clinician and payor stakeholders.

TypeBroad incumbent
Description

Lunit is a Korean medical AI company listed on KOSDAQ developing deep-learning-based imaging diagnostics, primarily in radiology and mammography. Comparable as a Korean peer medical AI company targeting hospital and screening center customers with regulatory-approved imaging SaMD.

TypeDirect peer
Description

Digital Diagnostics pioneered FDA-authorized autonomous AI diagnostics from retinal images (IDx-DR for diabetic retinopathy). A direct peer in retinal AI SaMD with established US regulatory success and similar clinical workflow (primary-care-based screening).

TypeOthers
Description

iCare, a Revenio Group subsidiary, manufactures the FDA-cleared DRSplus fundus imaging system and has an exploratory partnership to integrate with Dr. Noon CVD for US market entry. Comparable as an adjacent/imaging ecosystem partner whose commercial hardware footprint anchors Mediwhale's US go-to-market.

TypeDirect peer
Description

iHealthScreen provides AI-enabled retinal image analysis for systemic disease risk prediction (including cardiovascular), paralleling Mediwhale's Reti-CVD/Dr. Noon CVD approach. Targets similar clinical use cases (asymptomatic screening, metabolic disease management) with comparable regulatory positioning.

TypeOthers
Description

Topcon is a global manufacturer of fundus cameras and ophthalmic imaging systems, and is Mediwhale's distribution partner in Korea (bundling Dr. Noon with TRC-NW400). Included as a strategic ecosystem partner and adjacent incumbent whose installed base drives Mediwhale's hardware-enabled deployment.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors19 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mediwhale

Medical AI Diagnosticsmediwhale.com

Mediwhale is a Seoul-based medical AI company that develops deep learning software for retinal image analysis to predict cardiovascular and metabolic disease risk, serving hospitals and clinics across 8+ regulatory regions with its flagship Dr. Noon CVD product.

What Mediwhale does

Mediwhale is a Seoul-based medical AI company founded in October 2016 that develops deep learning software for analyzing retinal fundus photographs to predict cardiovascular and metabolic disease risk. The company's core product, Dr. Noon CVD, is the world's first regulatory-approved AI medical device for cardiovascular disease risk prediction using retinal imaging, demonstrating predictive accuracy comparable to cardiac CT scans without radiation exposure. The technology is built on proprietary deep learning models trained on over 2.1 million clinical data points across diverse populations and imaging devices, validated through 50+ peer-reviewed publications. The product portfolio includes Dr. Noon CVD (cardiovascular risk prediction), Dr. Noon Fundus (automated detection of glaucoma, cataracts, and retinal diseases), and pipeline product Dr. Noon CKD (chronic kidney disease prediction under regulatory review).

The company operates a B2B healthcare software business model, selling AI diagnostic examinations to hospitals, clinics, and health screening centers on a per-test basis (50,000-100,000 KRW per examination in Korea as a non-reimbursable test) supplemented by software licensing through distribution partnerships. Primary go-to-market is direct enterprise sales to major hospitals (Yonsei Severance, Naeun Hospital, Catholic University St. Vincent Hospital) complemented by channel partnerships with Dong-A ST for Korean clinic distribution and Topcon Korea Medical for bundled fundus camera solutions. The platform is commercially deployed across 111-170+ medical institutions in 8+ regulatory regions (Korea, EU CE MDR, UK MHRA, Australia TGA, Singapore HSA, Malaysia, Indonesia, India), with active expansion into Europe (Italy, Poland, Germany, Netherlands, France), Middle East (Dubai via GluCare.Health), Southeast Asia, and the US via FDA De Novo pursuit. The company has raised approximately 51.2 billion KRW (~$38M USD) across multiple funding rounds from 2020 to 2026 and is preparing for a KOSDAQ listing under the technology special track.

Mediwhale firmographics

Firmographics
Name
Mediwhale
Legal name
Mediwhale Inc.
Website
https://mediwhale.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Mediwhale is a Seoul-based medical AI company that develops deep learning software for retinal image analysis to predict cardiovascular and metabolic disease risk, serving hospitals and clinics across 8+ regulatory regions with its flagship Dr. Noon CVD product.
Ownership category
akta.pro rank

Mediwhale industry classification

Industry
Product category
Medical AI Diagnostics
NAICS
Software Publishers (5132), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAD
Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHDAAAEAH
Medical Imaging AI

Keywords

  • Retinal AI diagnostics
  • Cardiovascular risk prediction
  • Medical imaging software
  • AI medical devices
  • Disease prevention AI

Where Mediwhale is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

Mediwhale business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Others

Revenue model

  1. AI Diagnostic Software (Per Test/Examination): Mediwhale generates revenue through the sale of its Dr. Noon AI diagnostic examinations to healthcare institutions. Hospitals and clinics pay for the AI analysis service when conducting retinal scans on patients. In Korea, Dr. Noon CVD is available as a non-reimbursable diagnostic test at 50,000-100,000 KRW per examination. The company is pursuing insurance coverage through the Health Insurance Review and Assessment Service evaluation.
  2. Software Licensing and Distribution: Revenue generated through distribution partnerships where partners like Dong-A ST and Topcon distribute Dr. Noon solutions to hospitals and clinics across Korea. Partners handle sales and distribution while Mediwhale provides the software.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goDr. Noon CVD examination per session

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Mediwhale product offering

Product offering

Core offering

Mediwhale develops and sells AI-powered medical device software that analyzes retinal fundus photographs to predict cardiovascular disease risk and detect eye diseases. Its flagship Dr. Noon platform uses deep learning trained on over 2.1 million clinical data points to deliver non-invasive, radiation-free risk assessments with accuracy comparable to cardiac CT scans.

Product overview

Mediwhale offers a unified platform of retinal AI diagnostic solutions for preventive healthcare. The core product Dr. Noon CVD predicts cardiovascular disease risk through retinal imaging analysis with accuracy comparable to cardiac CT scans. Companion product Dr. Noon Fundus provides automatic detection of eye diseases (glaucoma, cataracts, retinal diseases). Pipeline product Dr. Noon CKD extends the platform to chronic kidney disease prediction. Reti-CVD was the original product name for the cardiovascular risk assessment AI that evolved into Dr. Noon CVD. All products leverage deep learning models trained on over 2.1 million clinical data points across diverse populations and imaging devices.

Differentiator

Problem solved

Functional benefit

Brands

  • Dr. Noon CVD: Retina-based AI risk prediction solution that assesses future cardiovascular disease risk using retinal imaging, with accuracy comparable to cardiac CT scans.
  • Dr. Noon Fundus
  • Dr. Noon CKD

Products and services

  • Dr. Noon CVD Retina-based AI software as a medical device that assesses future cardiovascular disease risk by analyzing retinal photographs, with predictive accuracy comparable to cardiac CT scans. Used by hospitals, clinics, and health screening centers for non-invasive, radiation-free CVD risk assessment.
  • Dr. Noon Fundus Retina-based AI solution that automatically detects three types of eye diseases—glaucoma, cataracts, and retinal diseases—from a single retinal photograph. Designed for use by ophthalmology clinics and primary care providers.
  • Dr. Noon CKD Retinal AI solution for chronic kidney disease prediction, designated as an innovative medical device in Korea. Currently under regulatory review with MFDS for approval.
  • Dr. Noon (Europe) Unified retinal AI solution combining eye disease diagnosis and cardiovascular risk prediction, CE MDR certified for commercialization in EU member states.

Quantifiable outcome

  • Cardiovascular risk prediction accuracy comparable to cardiac CT (coronary artery calcium scoring)
  • +3 more outcomes

Companies that use Mediwhale

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Mediwhale technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability3 records

Feature5 records

Mediwhale partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered strategic partner, distribution partner and regional partner.

  • Dong-A STstrategic partnerChannel Partner/ Reseller/ DistributorStrategic partnership for distribution of Mediwhale's AI retinal diagnostics across Korea. Following the partnership, adoption across internal medicine clinics increased rapidly with over 40,000 total examinations conducted.
  • Topcon Korea Medicaldistribution partnerChannel Partner/ Reseller/ DistributorSupply partnership with Topcon Korea Medical (subsidiary of Revenio Group) for Dr. Noon CVD bundled with Topcon fundus cameras (TRC-NW400) to hospitals and clinics.
  • GluCare.Healthregional partnerChannel Partner/ Reseller/ DistributorDubai-based diabetes clinic partnership for Dr. Noon CVD supply and UAE market expansion. Includes collaboration on UAE market entry and Dr. Noon CKD efficacy research.

Scale indicators8 records

Recent moves8 records

Expansion highlights8 records

Mediwhale competitors and assessment

Company assessment

Direct peers

  • Eyenuk: Eyenuk develops FDA-cleared AI for retinal image analysis (EyeArt for diabetic retinopathy). Directly comparable retinal AI SaMD vendor with similar regulatory milestones, hospital and clinic deployment model, and clinical screening value proposition.
  • AEYE Health: AEYE Health develops AI-based retinal screening for systemic and ocular disease detection, including cardiovascular risk assessment from fundus images. Directly comparable to Mediwhale in technology modality (retinal imaging + deep learning), customer base (primary care and endocrinology), and SaMD regulatory pathway.
  • Digital Diagnostics (IDx-DR): Digital Diagnostics pioneered FDA-authorized autonomous AI diagnostics from retinal images (IDx-DR for diabetic retinopathy). A direct peer in retinal AI SaMD with established US regulatory success and similar clinical workflow (primary-care-based screening).
  • iHealthScreen: iHealthScreen provides AI-enabled retinal image analysis for systemic disease risk prediction (including cardiovascular), paralleling Mediwhale's Reti-CVD/Dr. Noon CVD approach. Targets similar clinical use cases (asymptomatic screening, metabolic disease management) with comparable regulatory positioning.

Broad incumbents

  • Vuno: Vuno is a Korean medical AI company (KOSDAQ-listed) developing deep-learning solutions across multiple imaging and clinical data modalities. Peer in terms of geographic/regulatory context (Korea), target customer (hospitals), and SaMD commercialization model.
  • HeartFlow: HeartFlow provides non-invasive coronary CT-derived fractional flow reserve (FFR-CT) for cardiovascular disease diagnosis. Comparable as an established cardiac diagnostics SaMD company targeting similar specialist and primary care prescribers, though HeartFlow's modality (CT) differs from Mediwhale's retinal imaging.
  • Cleerly Health: Cleerly applies AI to coronary CT angiography for cardiovascular disease risk assessment. Comparable as an AI-CVD-diagnostics competitor positioning non-invasive imaging as a CT alternative—same end-point (CVD risk prediction) via a different imaging modality, addressing the same clinician and payor stakeholders.
  • Lunit: Lunit is a Korean medical AI company listed on KOSDAQ developing deep-learning-based imaging diagnostics, primarily in radiology and mammography. Comparable as a Korean peer medical AI company targeting hospital and screening center customers with regulatory-approved imaging SaMD.

Others

  • iCare (Revenio Group): iCare, a Revenio Group subsidiary, manufactures the FDA-cleared DRSplus fundus imaging system and has an exploratory partnership to integrate with Dr. Noon CVD for US market entry. Comparable as an adjacent/imaging ecosystem partner whose commercial hardware footprint anchors Mediwhale's US go-to-market.
  • Topcon Healthcare: Topcon is a global manufacturer of fundus cameras and ophthalmic imaging systems, and is Mediwhale's distribution partner in Korea (bundling Dr. Noon with TRC-NW400). Included as a strategic ecosystem partner and adjacent incumbent whose installed base drives Mediwhale's hardware-enabled deployment.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Mediwhale social profiles

Digital presence

Mediwhale compliance and trust

Trust signal

Compliance2 records

Mediwhale financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mediwhale leadership team

Management profile

Number of profiles

Profiles4 records

Mediwhale subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Mediwhale funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mediwhale M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mediwhale

What does Mediwhale do?

Mediwhale develops and sells AI-powered medical device software that analyzes retinal fundus photographs to predict cardiovascular disease risk and detect eye diseases. Its flagship Dr. Noon platform uses deep learning trained on over 2.1 million clinical data points to deliver non-invasive, radiation-free risk assessments with accuracy comparable to cardiac CT scans.

Is Mediwhale a public or private company?

Mediwhale is a private company. It is classified as venture growth investor backed and is currently operating.

When was Mediwhale founded?

Mediwhale was founded in 2016. It employs 11 to 50 people.

Where is Mediwhale based?

Mediwhale is headquartered in Seoul, South Korea, in the Asia region.

How does Mediwhale make money?

Two revenue lines are on record. AI Diagnostic Software (Per Test/Examination) is the primary driver. The others are software Licensing and Distribution.

Who are Mediwhale's main competitors?

Direct peers on record are Eyenuk, AEYE Health, Digital Diagnostics (IDx-DR) and iHealthScreen. Broad incumbents are Vuno, HeartFlow, Cleerly Health and Lunit. Others are iCare (Revenio Group) and Topcon Healthcare.

Does Mediwhale have an API?

No public API is recorded for Mediwhale.

What industry is Mediwhale in?

Mediwhale's product category is Medical AI Diagnostics. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HLACANAD, Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software. Its NAICS code is 5132 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
VenturesquareRetinal AI reveals clinical evidence at the American College of Preventive Cardiology... Mediwell accelerates its entry into the U.S.Mediwhale presented five research abstracts on its retinal AI cardiovascular risk assessment tool at the American Society of Preventive Cardiology conference in Scottsdale, Arizona. The company is pursuing FDA approval and collaborating with U.S. medical institutions to expand its market.KBRMSD Korea, KHIDI select 4 AI healthcare startups for global mentoringMSD Korea and the Korea Health Industry Development Institute held an AI healthcare innovation summit in Seoul, selecting four Korean digital health startups—Beamworks, BERTIS, Mediwhale, and Persely—for global mentoring and commercialization support. The three panel-selected winners will receive a combined 90 million won ($62,000) in funding, while all eight pitching companies become eligible for additional KHIDI support including preferential consideration under its global biohealth expansion program. MSD Korea has discussed potential partnerships with 51 Korean companies this year as part of efforts to strengthen Korea's healthcare and biopharmaceutical competitiveness.스타트업엔(StartupN)Mediwell unveils 'Doctor Eye CVD' at the American Diabetes Association... validating the prediction of cardiovascular disease risk with retinal AI.Mediwell presented its 'Doctor Eye CVD' device at the American Diabetes Association conference, validating cardiovascular disease risk prediction via retinal AI. The presentation is noted as overseas validation for domestic medical AI companies, but practical hurdles remain, including regulatory approvals, clinical data accumulation, and securing trust within the medical community.KBRMediwhale wins EU CE MDR approval for retinal AI cardiovascular risk toolMediwhale announced that its retinal AI solution Dr. Noon has received CE MDR certification from the European Union, enabling commercialization across all 27 EU member states. The certification is notable because it was granted for a "predictive" purpose—cardiovascular risk prediction—which is uncommon under the stringent MDR framework. The company is also pursuing FDA De Novo approval in the U.S. and planning a Kosdaq listing under the technology special track.VenturesquareMediwhale 'Doctor Eye' obtains European CE MDR... recognized as a medical device that 'predicts' cardiovascular risk.Mediwhale announced that its retinal AI solution DrNoon obtained CE MDR certification, enabling sales in all 27 EU countries. The device predicts cardiovascular risk with cardiac CT-level accuracy, and the certification recognizes cardiovascular risk prediction as an official use case. The company plans to expand globally, with DrNoon CVD undergoing FDA De Novo review.MobiHealthNewsKorean company behind retina-based CVD risk AI plans to go publicMediwhale, a South Korean medical AI startup, has raised $13 million in Series C funding led by private equity firm Premier Partners, bringing its total raised capital to $34 million. The company develops AI-powered software that analyzes retinal images to predict cardiovascular and chronic kidney disease risk, with its flagship product Dr Noon CVD deployed in over 170 hospitals globally. The funding will support US market entry, FDA De Novo regulatory approval, clinical trials, and preparations for a technology special listing on the KOSDAQ stock exchange in the first half of 2027.스타트업엔(StartupN)메디웨일, 200억 시리즈C 투자 유치…FDA 승인·IPO 동시 추진Medical AI company Mediwhale has completed a 20 billion won Series C investment round led by Premier Partners, with KB Investment and IMM Investment participating, bringing total accumulated investment to approximately 51.2 billion won. The company, founded in 2016, develops AI software that predicts cardiovascular and chronic kidney disease risk through retinal image analysis, with its core product 'Doctor Eye CVD' currently used in over 170 medical institutions domestically and internationally. Mediwhale is simultaneously pursuing U.S. FDA De Novo approval and a KOSDAQ IPO in the first half of next year as part of its global market entry strategy.Eyes On EyecareiCare and MediWhale partner on AI-based CVD retinal imagingiCare, a subsidiary of Revenio Group, and South Korea-based Mediwhale Inc. have agreed to explore a strategic collaboration integrating iCare's DRSplus fundus imaging system with Mediwhale's Dr. Noon CVD AI software to create a retinal imaging-based platform for cardiovascular disease risk assessment. iCare's device is already FDA 510(k) cleared and commercially available in the United States, while Mediwhale is pursuing FDA De Novo authorization with an estimated H1 2026 timeframe. The partnership aims to establish retinal screening as a tool for systemic health management beyond ophthalmology.MedicalstartupsTop 8 Myopia Treatment startups 2025The article presents a curated list of eight startups and companies involved in myopia treatment technologies, including AI diagnostics, digital therapeutics, and specialized contact lenses. It provides details on the specific focus areas and funding status for entities such as Mediwhale, Dopavision, and Myoptechs.